4 news items
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (NHL) and GLPG5201 in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter transformation
Galapagos Plans Clinical And Translational Data Presentations At EBMT Congress 2024
GLPG
4 Apr 24
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GLPG
4 Apr 24
presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL
Galapagos announces full year 2023 results and outlook for 2024
GLPG
22 Feb 24
GLPG5201 (CD19 CAR-T) in relapsed/refractory chronic lymphocytic leukemia (rrCLL
- Prev
- 1
- Next